{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:43:37Z","timestamp":1792874617433,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS Overseas Research Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01288-w","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T18:50:06Z","timestamp":1743101406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Remnant Cholesterol: Should it be a Target for Prevention of ASCVD?"],"prefix":"10.1007","volume":"27","author":[{"given":"Takahito","family":"Doi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Langsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge Gr\u00f8nne","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"25","key":"1288_CR1","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082\u2013143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","journal-title":"Circulation"},{"issue":"34","key":"1288_CR2","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","journal-title":"Eur Heart J"},{"issue":"8","key":"1288_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","volume":"37","author":"GJ Pearson","year":"2021","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129\u201350. https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016.","journal-title":"Can J Cardiol"},{"issue":"18","key":"1288_CR4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","unstructured":"Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993\u20132000. https:\/\/doi.org\/10.1001\/jama.2009.1619.","journal-title":"JAMA"},{"issue":"4","key":"1288_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","volume":"115","author":"N Sarwar","year":"2007","unstructured":"Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.637793.","journal-title":"Circulation"},{"issue":"4","key":"1288_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2012.08.1026.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1288_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345\u201352. https:\/\/doi.org\/10.1038\/ng.2795.","journal-title":"Nat Genet"},{"issue":"4","key":"1288_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364\u201373. https:\/\/doi.org\/10.1001\/jama.2018.20045.","journal-title":"JAMA"},{"issue":"1","key":"1288_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"issue":"47","key":"1288_CR10","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1093\/eurheartj\/ehab555","volume":"42","author":"T Doi","year":"2021","unstructured":"Doi T, Langsted A, Nordestgaard BG. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. Eur Heart J. 2021;42(47):4807\u201317. https:\/\/doi.org\/10.1093\/eurheartj\/ehab555.","journal-title":"Eur Heart J"},{"issue":"22","key":"1288_CR11","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"issue":"5","key":"1288_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/joim.13771","volume":"295","author":"T Doi","year":"2024","unstructured":"Doi T, Langsted A. Nordestgaard BG 2024 Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non-gemfibrozil fibrate trials. J Intern Med. 2024;295(5):707\u201310. https:\/\/doi.org\/10.1111\/joim.13771.","journal-title":"J Intern Med."},{"issue":"21","key":"1288_CR13","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2210645.","journal-title":"N Engl J Med"},{"issue":"24","key":"1288_CR14","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","volume":"79","author":"T Doi","year":"2022","unstructured":"Doi T, Langsted A, Nordestgaard BG. Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction. J Am Coll Cardiol. 2022;79(24):2383\u201397. https:\/\/doi.org\/10.1016\/j.jacc.2022.03.384.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1288_CR15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem"},{"issue":"25","key":"1288_CR16","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points\u2013a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944\u201358. https:\/\/doi.org\/10.1093\/eurheartj\/ehw152.","journal-title":"Eur Heart J"},{"key":"1288_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2019.05.011","volume":"286","author":"M Balling","year":"2019","unstructured":"Balling M, Langsted A, Afzal S, Varbo A, Davey Smith G, Nordestgaard BG. A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals. Atherosclerosis. 2019;286:97\u2013104. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.05.011.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1288_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547\u201363. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306249.","journal-title":"Circ Res"},{"issue":"4","key":"1288_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1161\/01.atv.15.4.534","volume":"15","author":"BG Nordestgaard","year":"1995","unstructured":"Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;15(4):534\u201342. https:\/\/doi.org\/10.1161\/01.atv.15.4.534.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1288_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/01.atv.11.3.569","volume":"11","author":"M Shaikh","year":"1991","unstructured":"Shaikh M, Wootton R, Nordestgaard BG, Baskerville P, Lumley JS, La Ville AE, et al. Quantitative studies of transfer in vivo of low density, Sf 12\u201360, and Sf 60\u2013400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb. 1991;11(3):569\u201377. https:\/\/doi.org\/10.1161\/01.atv.11.3.569.","journal-title":"Arterioscler Thromb"},{"key":"1288_CR21","doi-asserted-by":"publisher","first-page":"117141","DOI":"10.1016\/j.atherosclerosis.2023.05.010","volume":"379","author":"T Doi","year":"2023","unstructured":"Doi T, Langsted A, Nordestgaard BG. Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality. Atherosclerosis. 2023;379:117141. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.05.010.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1288_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MCO.0000000000000999","volume":"27","author":"D Elias-Lopez","year":"2024","unstructured":"Elias-Lopez D, Doi T, Nordestgaard BG, Kobylecki CJ. Remnant cholesterol and low-grade inflammation jointly in atherosclerotic cardiovascular disease: implications for clinical trials. Curr Opin Clin Nutr Metab Care. 2024;27(2):125\u201335. https:\/\/doi.org\/10.1097\/MCO.0000000000000999.","journal-title":"Curr Opin Clin Nutr Metab Care."},{"issue":"17","key":"1288_CR23","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","volume":"72","author":"P Libby","year":"2018","unstructured":"Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol. 2018;72(17):2071\u201381. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.1043.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1288_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/MED.0000000000000799","volume":"30","author":"T Doi","year":"2023","unstructured":"Doi T, Nordestgaard BG, Langsted A. Can remnant cholesterol (triglyceride-rich lipoproteins) reclassify estimated risk of atherosclerotic cardiovascular disease? Curr Opin Endocrinol Diabetes Obes. 2023;30(2):128\u201335. https:\/\/doi.org\/10.1097\/MED.0000000000000799.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"1288_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1373\/clinchem.2014.234146","volume":"61","author":"A Varbo","year":"2015","unstructured":"Varbo A, Freiberg JJ, Nordestgaard BG. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. Clin Chem. 2015;61(3):533\u201343. https:\/\/doi.org\/10.1373\/clinchem.2014.234146.","journal-title":"Clin Chem"},{"issue":"34","key":"1288_CR26","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","volume":"43","author":"BN Wadstrom","year":"2022","unstructured":"Wadstrom BN, Wulff AB, Pedersen KM, Jensen GB, Nordestgaard BG. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. Eur Heart J. 2022;43(34):3258\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/ehab705.","journal-title":"Eur Heart J"},{"issue":"24","key":"1288_CR27","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/eurheartj\/ehaa172","volume":"41","author":"M Kaltoft","year":"2020","unstructured":"Kaltoft M, Langsted A, Nordestgaard BG. Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. Eur Heart J. 2020;41(24):2288\u201399. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa172.","journal-title":"Eur Heart J"},{"issue":"1","key":"1288_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.13059","volume":"288","author":"A Langsted","year":"2020","unstructured":"Langsted A, Madsen CM, Nordestgaard BG. Contribution of remnant cholesterol to cardiovascular risk. J Intern Med. 2020;288(1):116\u201327. https:\/\/doi.org\/10.1111\/joim.13059.","journal-title":"J Intern Med"},{"issue":"47","key":"1288_CR29","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","volume":"42","author":"A Varbo","year":"2021","unstructured":"Varbo A, Nordestgaard BG. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction. Eur Heart J. 2021;42(47):4833\u201343. https:\/\/doi.org\/10.1093\/eurheartj\/ehab293.","journal-title":"Eur Heart J"},{"issue":"47","key":"1288_CR30","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, Boren J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehab551.","journal-title":"Eur Heart J"},{"key":"1288_CR31","doi-asserted-by":"publisher","first-page":"117556","DOI":"10.1016\/j.atherosclerosis.2024.117556","volume":"393","author":"T Doi","year":"2024","unstructured":"Doi T, Langsted A, Nordestgaard BG. Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial. Atherosclerosis. 2024;393:117556. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117556.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1288_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"1288_CR33","unstructured":"Meeusen JW, Ueda M, Nordestgaard BG, Remaley AT. 36 Lipids and Lipoproteins. In: Rifai N, Chiu RWK, Young I, Burnham C-AD, Wittwer CT. Tietz textbook of laboratory medicine. 7th ed. Philadelphia: Saunders; 2023."},{"issue":"24","key":"1288_CR34","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"AIM-HIGH Investigators","year":"2011","unstructured":"AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1107579.","journal-title":"N Engl J Med"},{"issue":"17","key":"1288_CR35","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"The Accord Study Group","year":"2010","unstructured":"The Accord Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1001282.","journal-title":"N Engl J Med"},{"issue":"9500","key":"1288_CR36","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"The FIELD study investigators","year":"2005","unstructured":"The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(05)67667-2.","journal-title":"Lancet"},{"issue":"3","key":"1288_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"The HPS2-THRIVE Collaborative Group","year":"2014","unstructured":"The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u201312. https:\/\/doi.org\/10.1056\/NEJMoa1300955.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01288-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01288-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01288-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T18:50:12Z","timestamp":1743101412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01288-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1288"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01288-w","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"9 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takahito Doi reports consultancies or talks sponsored by Kowa and Novo Nordisk. Anne Langsted reports consultancies or talks sponsored by Amarin and Novartis and is currently employed by Novo Nordisk. B\u00f8rge G. Nordestgaard reports consultancies or talks sponsored by AstraZeneca, Sanofi, Amgen, Amarin, Kowa, Novartis, Novo Nordisk, Esperion, Abbott, Arrowhead, and Marea.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No animal or human subjects by the authors were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"44"}}